Skip to main content
. 2017 Nov 2;25(9):1543–1553. doi: 10.3727/096504017X14886444100783

Figure 3.

Figure 3

SB-3CT and sorafenib synergistically inhibited HCC cell migration and MMP-2 expression. (A) SK-HEP-1 cells were exposed to 0, 2, 4, and 8 μmol/L SB-3CT for 48 h, and protein expression of MMP-2 was examined by Western blot. (B) Gelatin zymography assay was conducted to examine the effects of SB-3CT on the preform and active form of MMP-2/9 in SK-HEP-1 cells. (C) Sorafenib and SB-3CT synergistically inhibited MMP-2 expression of SK-HEP-1 cells. (D, E) Effect of sorafenib, SB-3CT, and combined sorafenib with SB-3CT therapy in wound healing and Transwell assays using SK-HEP-1 cells. Data represent the mean ± SD of three independent experiments. Scale bars: 100 μm. *p < 0.05, **p < 0.01.